John Libbey Eurotext

Bulletin du Cancer

MENU

News about... the proteasome inhibitor PS341 Volume 89, issue 1, Janvier 2002

Author
CNRS-Inserm, Institut de signalisation, Biologie du développement et cancer, parc Valrose, 06108 Nice Cedex 2.

The proteasome degradation system is one of the most efficient proteolytic process in living cells. We will focus here on a new compound, called PS341, which is the first proteasome inhibitor entering clinical phases. First results about its use in multiple myeloma or leukemic cells will be discussed.